Diabetologie und Stoffwechsel, Inhaltsverzeichnis Diabetologie und Stoffwechsel 2012; 7(6): 429-433DOI: 10.1055/s-0032-1330327 Editorial © Georg Thieme Verlag KG Stuttgart · New York Frühe Insulintherapie im Netzwerk individualisierter Therapie des Typ-2-Diabetes M. Hanefeld Artikel empfehlen Abstract Artikel einzeln kaufen Volltext Referenzen Literatur 1 Patel A, MacMahon S, Chalmers J et al. ADVANCE Collaborative Group Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358 (24) 2560-2572 2 Gerstein HC, Miller ME, Genuth S ACCORD Study Group et al. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med 2011; 364 (09) 818-828 3 Duckworth W, Abraira C, Moritz T et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360 (02) 129-139 . Epub 2008 Dec 17 4 Gerstein HC, Bosch J, Dagenais GR ORIGIN Trial Investigators et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012; 367 (04) 319-328 5 UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352 (9131) 837-853 6 UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352 (9131) 854-865 . Erratum in: Lancet 1998;352 (9139):1558. 7 Schernthaner G, Barnett AH, Betteridge DJ et al. Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis. Diabetologia 2010; 53 (07) 1258-1269 8 Matthaei S, Bierwirth R, Fritsche A et al. Medical antihyperglycaemic treatment of type 2 diabetes mellitus: update of the evidence-based guideline of the German Diabetes Association. Exp Clin Endocrinol Diabetes 2009; 117 (09) 522-557 9 Ray KK, Seshasai SR, Wijesuriya S et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 2009; 373 (9677) 1765-1772 10 Zoungas S, Patel A, Chalmers J et al. Severe hypoglycemia and risks of vascular events and death. N Engl J Med 2010; 363 (15) 1410-1418 11 McCoy RG, Van Houten HK, Ziegenfuss JY et al. Increased mortality of patients with diabetes reporting severe hypoglycemia. Diabetes Care 2012; 35 (09) 1897-1901 12 Ott P, Benke I, Stelzer J et al. „Diabetes in Germany“ (DIG) study. A prospective 4-year-follow-up study on the quality of treatment for type 2 diabetes in daily practice]. Dtsch Med Wochenschr 2009; 134 (07) 291-297 13 Huppertz E, Pieper L, Klotsche J et al. Diabetes Mellitus in German Primary Care: quality of glycaemic control and subpopulations not well controlled – results of the DETECT study. Exp Clin Endocrinol Diabetes 2009; 117 (01) 6-14 14 Tschöpe D, Bramlage P, Binz C et al. Incidence and predictors of hypoglycaemia in type 2 diabetes – an analysis of the prospective DiaRegis registry. BMC Endocr Disord 2012; 12 (01) 23 15 Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35 (06) 1364-1379 16 Groop LC, Bonadonna RC, DelPrato S et al. Glucose and free fatty acid metabolism in non-insulin-dependent diabetes mellitus. Evidence for multiple sites of insulin resistance. J Clin Invest 1989; 84 (01) 205-213 17 Del Prato S. Role of glucotoxicity and lipotoxicity in the pathophysiology of Type 2 diabetes mellitus and emerging treatment strategies. Diabet Med 2009; 26 (12) 1185-1192 18 Kjems LL, Kirby BM, Welsh EM et al. Decrease in beta-cell mass leads to impaired pulsatile insulin secretion, reduced postprandial hepatic insulin clearance, and relative hyperglucagonemia in the minipig. Diabetes 2001; 50 (09) 2001-2012 19 Poitout V, Robertson RP. Glucolipotoxicity: fuel excess and beta-cell dysfunction. Endocr Rev 2008; 29 (03) 351-366 20 Gleason CE, Gonzalez M, Harmon JS et al. Determinants of glucose toxicity and its reversibility in the pancreatic islet beta-cell line, HIT-T15. Am J Physiol Endocrinol Metab 2000; 279 (05) E997-E1002 21 Ceriello A. Hypothesis: the „metabolic memory”, the new challenge of diabetes. Diabetes Res Clin Pract 2009; 94 (2) 410-415 22 Li Y, Xu W, Liao Z et al. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of beta-cell function. Diabetes Care 2004; 27 (11) 2597-2602 23 Xu W, Li YB, Deng WP et al. Remission of hyperglycemia following intensive insulin therapy in newly diagnosed type 2 diabetic patients: a long-term follow-up study. Chin Med J 2009; 122 (21) 2554-2559 24 Chon S, Oh S, Kim SW et al. The effect of early insulin therapy on pancreatic β-cell function and long-term glycemic control in newly diagnosed type 2 diabetic patients. Korean J Intern Med 2010; 25 (03) 273-281 25 Bhattacharyya OK, Estey EA, Cheng AY ; Canadian Diabetes Association 2008 Update on the Canadian Diabetes Association 2008 clinical practice guidelines. Can Fam Physician 2009; 55 (01) 39-43 26 Sächsische Leitlinien zur Behandlung des Typ 2 Diabetes. 2010; 27 Pennartz C, Schenker N, Menge BA et al. Chronic reduction of fasting glycemia with insulin glargine improves first- and second-phase insulin secretion in patients with type 2 diabetes. Diabetes Care 2011; 34 (09) 2048-2053 28 Hanefeld M, Fleischmann H, Landgraf W et al. EARLY Study: Early Basal Insulin Therapy under Real-Life conditions in type 2 Diabetics. Diabetes, Stoffwechsel und Herz, Bd. 21 2012: 91-97 29 Fonseca V, Gill J, Zhou R et al. An analysis of early insulin glargine added to metformin with or without sulfonylurea: impact on glycaemic control and hypoglycaemia. Diabetes Obes Metab 2011; 13 (09) 814-822 30 Dormandy JA, Charbonnel B, Eckland DJ et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366 (9493) 1279-1289 31 Hanefeld M, Koehler C, Hoffmann C et al. Effect of targeting normal fasting glucose levels with basal insulin glargine on glycaemic variability and risk of hypoglycaemia: a randomized, controlled study in patients with early Type 2 diabetes. Diabet Med 2010; 27 (02) 175-180 32 Ceriello A. Basal insulin and cardiovascular and other outcomes. N Engl J Med 2012; 367 (18) 1762-1763 ; author reply 1763-1764 33 Hemkens LG, Grouven U, Bender R et al. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 2009; 52 (09) 1732-1744 34 Ruiter R, Visser LE, van Herk-Sukel MP et al. Risk of cancer in patients on insulin glargine and other insulin analogues in comparison with those on human insulin: results from a large population-based follow-up study. Diabetologia 2012; 55 (01) 51-62 35 Mellbin LG, Malmberg K, Norhammar A et al. Prognostic implications of glucose-lowering treatment in patients with acute myocardial infarction and diabetes: experiences from an extended follow-up of the Diabetes Mellitus Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) 2 Study. Diabetologia 2011; 54 (06) 1308-1317 36 Anselmino M, Malmberg K, Ohrvik J et al. Evidence-based medication and revascularization: powerful tools in the management of patients with diabetes and coronary artery disease: a report from the Euro Heart Survey on diabetes and the heart. Eur J Cardiovasc Prev Rehabil 2008; 15 (02) 216-223 37 Kahn SE, Haffner SM, Heise MA et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355 (23) 2427-2443 38 Riddle M et al. Attainment and Mainternance of HbA1c < 6.5 or 7 % with titrated basal insulin or Standard case in the ORIGIN trial. Diabetes Care 2012; accepted 39 Holman RR, Paul SK, Bethel MA et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359 (15) 1577-1589 40 Nathan DM, Cleary PA, Backlund JY et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353 (25) 2643-2653
